Compliance & Policy
UNEP-WHO report: fraction of 350,000 chemicals tested for EDCs
UNEP and WHO's first EDC science update since 2012 finds most of 350,000+ registered chemicals untested, with exposure costs above $1.1 trillion a year.

Waypoints
UNEP and WHO published the 240-page State of the Science of Endocrine-Disrupting Chemicals 2026 on 17 November 2026, the first update since 2012.
Only a small fraction of more than 350,000 registered chemicals and mixtures has been evaluated for endocrine-disrupting properties.
Health-related costs of EDC exposure exceed $1.1 trillion a year, and could reach one per cent or more of global GDP.
The report and its companion synthesis launched at the Global Framework on Chemicals conference in Geneva, running 16-20 November 2026.
Plastics treaty negotiations, where chemicals in plastics are contested, resume early next year.
Only a small fraction of the more than 350,000 chemicals and mixtures registered for use worldwide has been evaluated for endocrine-disrupting properties, according to State of the Science of Endocrine Disrupting Chemicals 2026, published by UNEP and WHO on 17 November 2026. The 240-page report is the first major global update since the 2012 assessment, and it puts health-related costs of exposure above $1.1 trillion a year — a figure the Associated Press describes as a conservative estimate covering treatment and lost productivity. UN News reports the costs could reach one per cent or more of global GDP.
The report responds to a request from the United Nations Environment Assembly to update the 2012 State of the Science assessment, itself preceded by a 2002 edition. WHO's publication record lists the new edition at 240 pages, edited by UNEP and WHO, and it reviews the most significant scientific advances since 2012.
What does the new assessment conclude?
Exposure to hormone-disrupting chemicals can begin before birth, the report concludes. WHO says stronger evidence now links EDCs to effects on fertility and reproductive development, brain development and neurological function, thyroid and hormone regulation, metabolism, immunity and cardiovascular health. Metabolic liver disease and possible kidney effects are named as newer concerns where important gaps remain.
In wildlife, exposure across fish, birds, amphibians and mammals is linked to impaired reproduction, development and behaviour. EDCs have been detected in blood, breast milk and cord blood. Sheila Aggarwal Khan of UNEP said the effects "can be long-lasting and, in some cases, irreversible."
Lead author Laura Vandenberg, a professor of environmental health sciences at the University of Massachusetts Amherst, told AP the science now offers "essentially a statement of irrefutable evidence linking EDCs to human health effects and also environmental damage," adding that "in many, many cases we know enough to act."
The testing and substitution gap
WHO states that people and wildlife are exposed to mixtures, yet many regulatory systems still assess chemicals one at a time. AP reports that testing programmes have expanded but that most have not led to regulation or controls on exposure.
Vandenberg described a "whack-a-mole problem": when a chemical such as bisphenol A is removed, a structurally similar or inadequately tested substitute often takes its place. The report says action is possible without resolving every uncertainty, and that reducing legacy contamination has reversed adverse effects in some cases.
Exposure routes covered in the coverage include ingestion, skin absorption, inhalation and contact with medical devices. EDCs are found in plastics, personal care products, pharmaceuticals, toys, household goods, electronics and pesticides.
What actions do the agencies recommend?
A companion synthesis, From Evidence to Action: Addressing Endocrine Disrupting Chemicals Across Sectors, sets out suggested practical actions for policymakers. WHO summarises the direction as:
- stronger regulation to phase out the most problematic chemicals and promote safer alternatives
- earlier identification of risks
- stronger scientific monitoring
- coordinated action across sectors, with particular attention to pregnancy, infancy and childhood
AP lists five action areas: protecting vulnerable groups, improving exposure monitoring and understanding, advancing chemical identification and testing, accounting for the costs of exposure, and strengthening regulations. WHO says the companion synthesis covers food packaging, cosmetics, toys, textiles, healthcare, agriculture, pharmaceuticals and waste, and that companies are urged to test early, disclose product ingredients and substitute chemicals proactively.
How did industry and campaigners react?
The regulatory backdrop differs by region. The American Chemistry Council, represented by Kimberly Wise White, argued that comprehensive frameworks such as the US Toxic Substances Control Act and the EU's REACH regulation are the most effective way to regulate plastic additives. Some countries are pushing to regulate chemicals in plastics within the global plastic pollution treaty talks, which AP says resume early next year. The plastics industry opposes new treaty restrictions and says existing conventions and national laws are better suited.
Bethanie Carrie Almroth, the UN Special Rapporteur on toxics and human rights, said responses need to move from reactive to proactive. Bjorn Beeler of the International Pollutants Elimination Network said the report strengthens countries pushing for controls.
The Health and Environment Alliance, in a statement dated 17 November 2026, said the report confirms strengthened evidence of associations between EDC exposure and adverse health outcomes and recognises the EU's role in identifying EDCs. Executive Director Genon K. Jensen called for "decisive action from the European Commission on restricting EDCs." HEAL urged restrictions on groups of problematic EDCs through the REACH restrictions roadmap, new REACH authorisations and new sectoral requirements, for example for cosmetic products, in line with the EU Chemicals Strategy for Sustainability.
What is at stake for labs and product streams?
The report offers options for decision-makers rather than binding rules. Any change to how endocrine disruptors are identified or restricted would reach laboratories and product supply chains through TSCA in the United States and REACH in the EU — the instruments both industry and campaigners cite.
The new edition notes progress in the range of documented health effects, exposure science, testing and assessment methods, and understanding of the socioeconomic costs of regulatory inaction, according to WHO. The documented costs of exposure are not fully captured in current estimates, the report says.
Both documents were launched in Geneva at the first International Conference of the Global Framework on Chemicals, which runs from 16 to 20 November 2026.
What happens next?
The Global Framework on Chemicals conference continues in Geneva until 20 November 2026. Negotiations on the global plastic pollution treaty resume early next year, where chemicals in plastics are among the contested issues. HEAL's calls are directed at the European Commission. The sources set out calls for action rather than a dated restriction — and the plastics treaty round will decide whether chemicals-in-plastics controls gain treaty force.
via casrai.org (Source)
More from Rebecca Stone
Show full bio
News editor covering companies, deals and strategy in Circular economy and the environmental industry at Circular Wire.
516 articles